Literature DB >> 25910842

Predictive imaging marker of bevacizumab efficacy: perfusion MRI.

Whitney B Pope1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25910842      PMCID： PMC4490878          DOI： 10.1093/neuonc/nov067

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  11 in total

1.  MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.

Authors:  W B Pope; A Lai; P Nghiemphu; P Mischel; T F Cloughesy
Journal:  Neurology       Date:  2006-04-25       Impact factor: 9.910

2.  MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy.

Authors:  Marc C Chamberlain
Journal:  Neurology       Date:  2006-12-12       Impact factor: 9.910

3.  Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment.

Authors:  Whitney B Pope; Hyun J Kim; Jing Huo; Jeffry Alger; Matthew S Brown; David Gjertson; Victor Sai; Jonathan R Young; Leena Tekchandani; Timothy Cloughesy; Paul S Mischel; Albert Lai; Phioanh Nghiemphu; Syed Rahmanuddin; Jonathan Goldin
Journal:  Radiology       Date:  2009-07       Impact factor: 11.105

4.  Bevacizumab for newly diagnosed glioblastoma.

Authors:  Olivier L Chinot; Wolfgang Wick; Timothy Cloughesy
Journal:  N Engl J Med       Date:  2014-05-22       Impact factor: 91.245

5.  Dynamic-susceptibility contrast agent MRI measures of relative cerebral blood volume predict response to bevacizumab in recurrent high-grade glioma.

Authors:  Kathleen M Schmainda; Melissa Prah; Jennifer Connelly; Scott D Rand; Raymond G Hoffman; Wade Mueller; Mark G Malkin
Journal:  Neuro Oncol       Date:  2014-01-15       Impact factor: 12.300

6.  Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma.

Authors:  Philipp Kickingereder; Benedikt Wiestler; Sina Burth; Antje Wick; Martha Nowosielski; Sabine Heiland; Heinz-Peter Schlemmer; Wolfgang Wick; Martin Bendszus; Alexander Radbruch
Journal:  Neuro Oncol       Date:  2015-03-09       Impact factor: 12.300

7.  Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma.

Authors:  J J C Verhoeff; C Lavini; M E van Linde; L J A Stalpers; C B L M Majoie; J C Reijneveld; W R van Furth; D J Richel
Journal:  Ann Oncol       Date:  2010-01-11       Impact factor: 32.976

8.  Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.

Authors:  A D Norden; G S Young; K Setayesh; A Muzikansky; R Klufas; G L Ross; A S Ciampa; L G Ebbeling; B Levy; J Drappatz; S Kesari; P Y Wen
Journal:  Neurology       Date:  2008-03-04       Impact factor: 9.910

9.  A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients.

Authors:  A Gregory Sorensen; Tracy T Batchelor; Wei-Ting Zhang; Poe-Jou Chen; Priscilla Yeo; Meiyun Wang; Dominique Jennings; Patrick Y Wen; Johanna Lahdenranta; Marek Ancukiewicz; Emmanuelle di Tomaso; Dan G Duda; Rakesh K Jain
Journal:  Cancer Res       Date:  2009-06-23       Impact factor: 12.701

10.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Authors:  Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544
View more
  3 in total

1.  Dynamic susceptibility contrast MRI measures of relative cerebral blood volume continue to show promise as an early response marker in the setting of bevacizumab treatment.

Authors:  Jerrold L Boxerman; Kathleen M Schmainda; Zheng Zhang; Daniel P Barboriak
Journal:  Neuro Oncol       Date:  2015-09-11       Impact factor: 12.300

2.  Evidence for rCBV as an early response marker following bevacizumab treatment.

Authors:  Whitney B Pope
Journal:  Neuro Oncol       Date:  2015-11       Impact factor: 12.300

3.  Response assessment of bevacizumab therapy in GBM with integrated 11C-MET-PET/MRI: a feasibility study.

Authors:  Cornelius Deuschl; Christoph Moenninghoff; Sophia Goericke; Julian Kirchner; Susanne Köppen; Ina Binse; Thorsten D Poeppel; Harald H Quick; Michael Forsting; Lale Umutlu; Ken Herrmann; Joerg Hense; Marc Schlamann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-03-03       Impact factor: 9.236
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.